Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study

Abstract

Clinical features of COVID-19 have been mostly described in hospitalized patients with and without ICU admission. Yet, up to 80% of patients are managed in an outpatient setting. This population is poorly documented. In France, health authorities recommend outpatient management of patients presenting mild-to-moderate COVID-19 symptoms. The aim of this study was to describe their clinical characteristics. The study took place in an emergency medical dispatching center located in the Greater Paris region. Patients included in this survey met confirmed COVID-19 infection criteria according to the WHO definition. We investigated clinical features and classified symptoms as general, digestive, ear-nose-throat, thoracic symptoms, and eye disease. Patients were included between March 24 and April 6 2020. 1487 patients included: 700 (47%) males and 752 (51%) females, with a median age of 44 (32-57) years. In addition to dry cough and fever reported in more than 90% of cases, the most common symptoms were general symptoms: body aches/myalgia (N = 845; 57%), headache (N = 824; 55%), and asthenia (N = 886; 60%); shortness of breath (N = 479; 32%) and ear-nose-throat symptoms such as anosmia (N = 415; 28%) and ageusia (N = 422; 28%). Chest pain was reported in 320 (21%) cases and hemoptysis in 41 (3%) cases. The main difference between male and female patients was an increased prevalence of ear-nose-throat symptoms as well as diarrhea, chest pains, and headaches in female patients. General symptoms and ear-nose-throat symptoms were predominant in COVID-19 patients presenting mild-to-moderate symptoms. Shortness of breath and chest pain were remarkably frequent.

Risk factors and outcome of COVID-19 in patients with hematological malignancies

“…Of course, as with any risk score obtained form a single study, its validation and improvement in independent patient cohorts is required before one can suggest that it should be used to better predict the outcome of COVID-19 in patients with hematological malignancies. Characteristics of COVID-19 symptoms in hematological patients share similarities with the general population [20], with fever, dry cough, fatigue and diarrhea being the most common initial signs/symptoms of infection. Systemic symptoms, however, were more common than URTD symptoms, as has also been reported in the general population.…”

Neuromuscular presentations in patients with COVID-19

“…We identified 96 studies of COVID-19-related myalgia. After exclusion of descriptive reviews, data in other than English language, and duplicate studies, we selected 13 studies and 2 meta-analysis comprising of 10 and 55 studies, respectively (Table 1) [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21].…”

Association of Neuronal Injury Blood Marker Neurofilament light chain with mild-to-moderate COVID-19

“…[1][2][3] Headache and anosmia have been frequently described as neurological symptoms of mild-to-moderate COVID-19 but a direct impact of COVID-19 on neuronal integrity has not been clari ed yet. 4 Therefore, a neuronal biomarker would be extremely useful to elucidate neuro-axonal injury during an infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and in the post-infection follow up period. Serum neuro lament light chain (sNfL) has recently been considered as a speci c biomarker to quantitate neuro-axonal damage in several disorders of the peripheral and central nervous system.…”